Stock Financial Ratios, Dividends, Split History

MYL / Mylan N.V. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price38.31
Volume2,094,500.00
Market Cap ($M)22,095.94
Enterprise Value ($M)23,612.74
Book Value ($M)13,176.70
Book Value / Share25.56
Price / Book1.66
NCAV ($M)-15,246.50
NCAV / Share-29.58
Price / NCAV-1.31
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 534,500,000
Common Shares Outstanding 514,781,709
Weighted Average Number Of Diluted Shares Outstanding 536,700,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.02
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Assets35,184.50
Liabilities22,007.80
Quick Ratio0.65
Current Ratio1.06
Income Statement (mra) ($M)
Sales Revenue Goods Net11,760,000,000.00
Equity Method Investment Summarized Financial Information Revenue473,000,000.00
Sales Revenue Net11,907,700,000.00
Other Sales Revenue Net147,700,000.00
Operating Income1,437.10
Net Income696.00
Earnings Per Share Diluted1.30
Earnings Per Share Basic1.30
Cash Flow Statement (mra) ($M)
Cash From Operations2,064.80
Cash from Investing-905.40
Cash from Financing-905.40
Identifiers and Descriptors
CUSIPN59465109
Central Index Key (CIK)1623613
Related CUSIPS
N59465959 062853010 001103120 0N5946510 N59465909 628530907 010235618 628530957

Split History

Stock splits are used by Mylan N.V. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Mylan Stock Looks Cheap, but Don’t Overlook These Risks

2018-06-21 investorplace
Mylan N.V. (NASDAQ:MYL) has been a battleground stock in 2018. And that’s with good reason, Mylan stock has seen plenty of good news, but also a number of setbacks. EpiPen is a perfect example. The brand brought Mylan shame and a substantial fine, but it’s also in short supply now, continuing to lead to strong ongoing profits. (135-0)

Amgen Should Rebound On Aimovig And Kyprolis Revenue

2018-06-20 seekingalpha
Amgen (NASDAQ:AMGN) is a large-cap biotech company, in fact, one of the original biotechs. It pays a dividend, which is rare among biotechs. It also has an extensive pipeline that should offset its patent cliffs and return it to being a growth stock. (144-0)

Your Daily Pharma Scoop: Resverlogix Cleared For Trial, ViiV Positive Data, Eli Lilly Up

2018-06-16 seekingalpha
Resverlogix (OTCPK:RVXCF) recently announced that the FDA has accepted the statistical analysis plan and endpoints for the large-scale Phase 3 trial of assessment of cardiovascular benefits of its lead candidate apabetalone. The projected endpoint of the study is the reduction of major adverse cardiovascular events (MACE) in a high cardiovascular risk in type 2 diabetes population. The same population often also displayed low levels of high density lipoproteins (HDL). (164-0)

Citadel's Bet Avrobio Does Not Suit Me At The Moment

2018-06-16 seekingalpha
Morgan Stanley, Cowen, Wells Fargo and Wedbush Pacgrow will help the company sell 22,313,687 shares at $16-$18 per share. (181-8)

20 Nasdaq-100 Stocks That Will Heat Up 2H18

2018-06-15 investorplace
Unless you’ve been living under a rock, you know that the narrative surrounding broad markets — it’s been one of strife since late January until the recent rally. Volatility spiked and the S&P 500 Index still sits almost 3% below late-January highs. (2079-8)

CUSIP: N59465109